Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Association Areas of the Cortex01:21

Association Areas of the Cortex

5.5K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
5.5K
Dementia01:30

Dementia

139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598
Long-term Depression01:03

Long-term Depression

2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Neurology·2026
Same author

Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.

Nature communications·2026
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.

Neurology·2026
Same author

Investigating AD and non-AD [<sup>18</sup>F]flortaucipir distribution patterns in a memory clinic cohort.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same journal

Integrating sexual health into care for patients with cancer and chronic illness.

Nature reviews. Disease primers·2026
Same journal

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Jul 19, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K

Frontotemporal lobar degeneration.

Murray Grossman1, William W Seeley2,3, Adam L Boxer4

  • 1Department of Neurology and Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.

Nature Reviews. Disease Primers
|August 10, 2023
PubMed
Summary
This summary is machine-generated.

Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementia. Advances in understanding FTLD mutations and developing biomarkers are crucial for new disease-modifying treatments.

More Related Videos

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K
Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy
12:09

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy

Published on: August 5, 2014

18.1K

Related Experiment Videos

Last Updated: Jul 19, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K
Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy
12:09

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy

Published on: August 5, 2014

18.1K

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Frontotemporal lobar degeneration (FTLD) is a leading cause of early-onset dementia.
  • FTLD is characterized by social-emotional-behavioral and/or language changes, potentially with motor disorders.
  • Approximately 20-25% of FTLD cases are linked to specific genetic mutations.

Purpose of the Study:

  • To review advances in understanding FTLD genetics and pathology.
  • To highlight the challenges and progress in developing diagnostic biomarkers for sporadic FTLD.
  • To discuss the potential of novel therapeutic strategies for FTLD.

Main Methods:

  • Review of current literature on FTLD genetics, pathology, and biomarkers.
  • Analysis of the role of tau, TDP-43, and FUS protein inclusions in FTLD subtypes.
  • Examination of emerging diagnostic and therapeutic approaches.

Main Results:

  • FTLD subtypes include FTLD-tau, FTLD-TDP, and FTLD-FET.
  • Genetic mutations have improved understanding and treatment development for FTLD.
  • Definitive biomarkers for sporadic FTLD pathology remain elusive, hindering treatment development.

Conclusions:

  • Sophisticated biofluid and imaging biomarkers are advancing disease monitoring and treatment response assessment.
  • Novel symptomatic treatments, such as transcranial direct current stimulation, show promise.
  • Continued research into FTLD genetics, pathology, and biomarkers is essential for effective disease modification.